Thursday, 2nd of July – 13.30 – 14.30 hrs
Protein-based drugs are one of the most important classes of therapeutics. Despite this, the field of rational design of biologics remains challenging. Recently, in silico technologies have emerged as valuable tools in both discovery and development. In this webinar, we will discuss how a range of computational solutions can be used to overcome typical problems in the field including structure prediction, epitope mapping, protein engineering and developability.
In this webinar we will discuss:
– Protein structure prediction
– Protein docking/epitope mapping
– In silico mutagenesis
– Protein developability
Sign up for this webinar via this link
Schrödinger’s physics-based computational platform leverages a deep understanding of physics, chemistry, and predictive modeling to accelerate innovation.
Their platform enables the collaborators to discover high-quality, novel molecules more rapidly, at lower cost, and with a higher likelihood of success compared to traditional methods.
About the presenters:
Jenny Brookes received her PhD in Theoretical Condensed Matter Physics at University College London (UCL), UK in 2008. She was then awarded a Sir Henry Wellcome Post Doctoral Fellowship from the Wellcome Trust UK for 4 years. During which she worked at MIT investigating sensing in olfaction and then Harvard investigating efficient photosynthetic processes. Subsequently she moved back to the UK and UCL to join the i-sense – an £11M EPSRC IRC in Early Warning Sensing Systems for Infectious Diseases and Antimicrobial Resistance as the lead theoretical & computational biophysicist investigating protein-protein interactions for optimizing HIV and ‘flu biosensors with respect to sensitivity and selectivity.
Dan Cannon received his BSc (Hons) in Pure and Applied Chemistry from the University of Strathclyde, Glasgow in 2011, where he remained for his PhD, under the supervision of Prof. Tell Tuttle, using various in silico techniques to understand the behavior of peptides in solution and at interfaces. In 2016, he began working at MedImmune in Cambridge UK, using computational approaches for therapeutic protein design before joining Schrödinger in August of 2018 as a Senior Applications Scientist, where he uses his expertise in biologics to support customers in getting the most from the biologics suite and helps them to add substantial value to projects.